Q2 EPS Forecast for Compass Therapeutics Lowered by Analyst

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Compass Therapeutics in a report released on Tuesday, April 1st. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.14). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS and FY2026 earnings at ($0.76) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01).

Several other brokerages also recently issued reports on CMPX. Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. Guggenheim reiterated a "buy" rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Stock Up 10.6 %

Shares of CMPX stock traded up $0.17 during trading hours on Friday, reaching $1.76. 7,896,601 shares of the stock traded hands, compared to its average volume of 849,568. The firm has a market capitalization of $243.24 million, a PE ratio of -4.74 and a beta of 1.40. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The business has a fifty day moving average price of $2.67 and a 200 day moving average price of $2.10.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MPM Bioimpact LLC raised its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter valued at $11,293,000. Tang Capital Management LLC lifted its position in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. Rock Springs Capital Management LP boosted its stake in Compass Therapeutics by 2.7% during the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after buying an additional 150,336 shares in the last quarter. Finally, Blue Owl Capital Holdings LP increased its holdings in Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock valued at $4,284,000 after buying an additional 75,000 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 28.50% of the stock is currently owned by company insiders.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.